Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey

Sarah Glewis*, Mei Krishnasamy, Senthil Lingaratnam, Sam Harris, Craig Underhill, Chloe Georgiou, Mark Warren, Robert Campbell, Maarten IJzerman, Mussab Fagery, Ian Campbell, Jennifer H Martin, Jeanne Tie, Marliese Alexander, Michael Michael

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Downloads (Pure)

Abstract

This study explored the acceptability of a novel pharmacist-led pharmacogenetics (PGx) screening program among patients with cancer and healthcare professionals (HCPs) taking part in a multicenter clinical trial of PGx testing (PACIFIC-PGx ANZCTR:12621000251820). Medical oncologists, oncology pharmacists, and patients with cancer from across four sites (metropolitan/regional), took part in an observational, cross-sectional survey. Participants were recruited from the multicenter trial. Two study-specific surveys were developed to inform implementation strategies for scaled and sustainable translation into routine clinical care: one consisting of 21 questions targeting HCPs and one consisting of 17 questions targeting patients. Responses were collected from 24 HCPs and 288 patients. The 5-to-7-day PGx results turnaround time was acceptable to HCP (100%) and patients (69%). Most HCPs (92%) indicated that it was appropriate for the PGx clinical pharmacist to provide results to patients. Patients reported equal preference for receiving PGx results from a doctor/pharmacist. Patients and HCPs highly rated the pharmacist-led PGx service. HCPs were overall accepting of the program, with the majority (96%) willing to offer PGx testing to their patients beyond the trial. HCPs identified that lack of financial reimbursements (62%) and lack of infrastructure (38%) were the main reasons likely to prevent/slow the implementation of PGx screening program into routine clinical care. Survey data have shown overall acceptability from patients and HCPs participating in the PGx Program. Barriers to implementation of PGx testing in routine care have been identified, providing opportunity to develop targeted implementation strategies for scaled translation into routine practice.

Original languageEnglish
Pages (from-to)2700-2708
Number of pages9
JournalClinical and Translational Science
Volume16
Issue number12
Early online date25 Oct 2023
DOIs
Publication statusPublished - Dec 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Fingerprint

Dive into the research topics of 'Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey'. Together they form a unique fingerprint.

Cite this